NCT04026256View on ClinicalTrials.gov

Bone Modeling Effects of Combined Anabolic/Antiresorptive Administration

PHASE4CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

September 2, 2019

Primary Completion Date

April 18, 2022

Study Completion Date

April 18, 2022

Conditions
Postmenopausal Osteoporosis
Interventions
DRUG

Teriparatide

teriparatide daily subcutaneous injection

DRUG

Denosumab

denosumab subcutaneous injection

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

NIH

lead

Massachusetts General Hospital

OTHER

NCT04026256 - Bone Modeling Effects of Combined Anabolic/Antiresorptive Administration | Biotech Hunter | Biotech Hunter